TLRs are important inflammatory factors in atherosclerosis and may be a therapeutic target

Medical Hypotheses

Volumn 70, Issue 2, 2008, Pages 314-316

  Liu, Yunfang ^a   Yu, Huiming ^a   Zhang, Yun ^b   Zhao, Yuxia ^c  

^a SHANDONG UNIVERSITY   (China)

^b BEIJING HOSPITAL   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; POLYPEPTIDE ANTIBIOTIC AGENT; TOLL LIKE RECEPTOR;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CELL PROLIFERATION; DISEASE COURSE; MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ANIMALS; ATHEROSCLEROSIS; HUMANS; INFLAMMATION MEDIATORS; MODELS, CARDIOVASCULAR; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 37349081540     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2007.05.030     Document Type: Article

References (25)

1. Cleland S.J., Sattar N., Petrie J.R., Forouhi N.G., Elliott H.L., and Connell J.M. Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clin Sci (Lond) 98 (2000) 531-535
2. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 104 (2001) 365-372
3. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 1 (2001) 135-145
4. Abreu M.T., and Arditi M. Innate immunity and toll-like receptors: clinical implications of basic science research. J Pediatr 144 (2004) 421-429
5. Xu X.H., Shah P.K., Faure E., et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 104 (2001) 3103-3108
6. Edfeldt K., Swedenborg J., Hansson G.K., and Yan Z.Q. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 105 (2002) 1158-1161
7. Brand K., Page S., Walli A.K., Neumeier D., and Baeuerle P.A. Role of nuclear factor-kappaB in atherogenesis. Exp Physiol 82 (1997) 297-304
8. Akira S., Takeda K., and Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2 (2001) 675-680
9. Medzhitov R., Preston-Hurlburt P., and Janeway Jr. C.A. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388 (1997) 394-397
10. Libby P., and Ridker P.M. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med 116 (2004) 9S-16S
11. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 138 (1999) S419-S420
12. Shah P.K. Plaque disruption and thrombosis: potential role of inflammation and infection. Cardiol Clin 17 (1999) 271-281
13. Libby P., Egan D., and Skarlatos S. Roles of infectious agents in atherosclerosis and restenosis. Circulation 96 (1997) 4095-4103
14. Byrne G.I., and Kalayoglu M. Chlamydia pneumoniae and atherosclerosis: links to the disease process. Am Heart J 138 (1999) S488-S490
15. Jackson L.A., Campbell L.A., Schmidt R.A., et al. Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma: evaluation of the innocent bystander hypothesis. Am J Pathol 150 (1997) 1785-1790
16. Vabulas R.M., Ahmad-Nejad P., da Costa C., et al. Endocytosed HSP60s use toll-like receptor 2 (TLR2) and TLR4 to activate the toll/interleukin-1 receptor signaling pathway in innate immune cells. J Biol Chem 276 (2001) 31332-31339
17. Okamura Y., Watari M., Jerud E.S., et al. The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem 276 (2001) 10229-10233
18. Bulut Y., Faure E., Thomas L., et al. Chlamydial heat shock protein 60 activates macrophages and endothelial cells through Toll-like receptor 4 and MD2 in a MyD88-dependent pathway. J Immunol 168 (2002) 1435-1440
19. Miller Y.I., Viriyakosol S., Binder C.J., Feramisco J.R., Kirkland T.N., and Witztum J.L. Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells. J Biol Chem 278 (2003) 1561-1568
20. Castrillo A., Joseph S.B., Vaidya S.A., et al. Crosstalk between LXR and toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism. Mol Cell 12 (2003) 805-816
21. Moazed T.C., Campbell L.A., Rosenfeld M.E., et al. Chlamydia pneumoniae infection accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. J Infect Dis 180 (1999) 238-241
22. Campbell L.A., and Kuo C.-C. Mouse models of Chlamydia pneumoniae infection and atherosclerosis. Am Heart J 138 (1999) S516-S518
23. Hu H., Pierce G.N., and Zhong G. The atherogenic effects of chlamydia are dependent on serum cholesterol and specific Chlamydia pneumoniae. J Clin Invest 103 (1999) 747-753
24. Michelsen K.S., Wong M.H., Shah P.K., et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci 101 (2004) 10679-10684
25. Kiechl S., Lorenz E., Reindl M., et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 347 (2002) 185-192